ResMed Inc. (NYSE:RMD) is expected to post earnings of $1.47 per share

Equity research analysts expect ResMed Inc. (NYSE:RMD) to report earnings of $1.47 per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts provided estimates of ResMed’s earnings, with estimates ranging from $1.42 to $1.49. ResMed reported earnings per share of $1.41 in the same quarter last year, suggesting a positive year-over-year growth rate of 4.3%. The company is expected to announce its next quarterly earnings report after the market closes on Thursday, January 27.

On average, analysts expect ResMed to report annual earnings of $6.26 per share for the current year, with EPS estimates ranging from $5.93 to $6.57. For next year, analysts expect the company to post earnings of $6.92 per share, with EPS estimates ranging from $6.51 to $7.39. Zacks EPS averages are an average average based on a survey of analysts who provide coverage for ResMed.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, October 28. The medical equipment supplier reported earnings per share of $1.51 for the quarter, beating analysts’ consensus estimate of $1.35 by $0.16. ResMed had a return on equity of 28.46% and a net margin of 14.92%. The company posted revenue of $904.00 million for the quarter, versus a consensus estimate of $858.20 million. In the same quarter last year, the company earned earnings per share of $1.27. The company’s revenue for the quarter increased by 20.2% compared to the same quarter last year.

RMD has been the subject of a number of research analyst reports. Robert W. Baird upgraded ResMed from a “neutral” rating to an “outperforming” rating and raised its price target for the company from $270.00 to $300.00 in a research note on Thursday. Royal Bank of Canada raised its price target on ResMed from $227.00 to $234.00 and gave the stock an “underperforming” rating in a research note on Thursday. Macquarie upgraded ResMed from a “neutral” rating to an “outperforming” rating in a Monday, December 6 report. Finally, CLSA upgraded ResMed from an “underperforming” rating to an “overperforming” rating in a Friday, October 22 report. Two investment analysts gave the stock a sell rating, six gave the company a hold rating and four gave the company a buy rating. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $260.50.

(A d)

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Action ResMed traded at $0.46 in Friday’s midday session, hitting $252.16. The company’s stock had a trading volume of 561,755 shares, compared to an average volume of 426,775. The stock’s 50-day simple moving average is $256.23 and its 200-day simple moving average is $264.73. The company has a debt ratio of 0.26, a current ratio of 2.54 and a quick ratio of 1.73. ResMed has a 52-week low of $179.37 and a 52-week high of $301.34. The stock has a market capitalization of $36.74 billion, a P/E ratio of 73.95, a PEG ratio of 2.54 and a beta of 0.30.

The company also recently announced a quarterly dividend, which was paid on Thursday, December 16. Shareholders of record on Thursday, November 11 received a dividend of $0.42. The ex-dividend date was Tuesday, November 9. This represents a dividend of $1.68 on an annualized basis and a yield of 0.67%. ResMed’s dividend payout ratio is currently 49.27%.

In related news, COO Robert Andrew Douglas sold 8,000 shares of the company in a transaction on Monday, November 15. The stock was sold at an average price of $271.75, for a total value of $2,174,000.00. The transaction was disclosed in a document filed with the SEC, accessible via this link. Also, CFO Brett Sandercock sold 2,500 shares of the company in a transaction on Monday, January 10. The stock was sold at an average price of $235.00, for a total value of $587,500.00. Disclosure of this sale can be found here. Insiders sold 39,691 shares of the company worth $10,330,553 in the past 90 days. Insiders of the company own 1.42% of the shares of the company.

Institutional investors and hedge funds have recently increased or reduced their stakes in the stock. Liberty Wealth Management LLC increased its position in ResMed shares by 24,552.0% during the second quarter. Liberty Wealth Management LLC now owns 6,163 shares of the medical equipment supplier worth $25,000 after acquiring 6,138 additional shares last quarter. MUFG Americas Holdings Corp acquired a new position in ResMed stock during Q3 worth approximately $26,000. D Orazio & Associates Inc. acquired a new position in ResMed stock during Q3 worth approximately $30,000. JJJ Advisors Inc. increased its position in ResMed shares by 32.9% during the third quarter. JJJ Advisors Inc. now owns 194 shares of the medical equipment supplier worth $51,000 after acquiring 48 more shares in the last quarter. Finally, Dark Forest Capital Management LP acquired a new position in shares of ResMed during Q3 worth approximately $75,000. 65.12% of the shares are held by hedge funds and other institutional investors.

About ResMed

ResMed, Inc is committed to providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices are transforming care for people with sleep apnea, chronic obstructive pulmonary disease or COPD and other chronic conditions. The Company operates through the following segments: Sleep and Respiratory Care, and Software as a Service.

Further reading: Dividend realizers

Get a Free Copy of Zacks Research Report on ResMed (RMD)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for ResMed (NYSE: RMD)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in ResMed right now?

Before you consider ResMed, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and ResMed wasn’t on the list.

While ResMed currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Comments are closed.